Cambridge, Mass. (February 6, 2018) – Kymera Therapeutics LLC, a biotechnology company pioneering targeted-protein degradation as a transformative new approach to creating breakthrough medicines for patients, today announced the appointment of industry veteran Mark Nuttall, Ph.D., as chief business officer. Dr. Nuttall joins Kymera from Sanofi Genzyme where he led business development and licensing for Immunology and Inflammation and Neuroscience. The company also announced the appointment of Don Nicholson, Ph.D., CEO of Nimbus Therapeutics, to its Board of Directors.
Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies
CAMBRIDGE, Mass., Oct. 30, 2017 /PRNewswire/ — Kymera Therapeutics LLC today announced a $30M Series A Financing round to advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases. The company is pioneering a novel targeted protein degradation platform and approach to accelerate drug discovery and development, and deliver on its mission. The round was led by Atlas Venture, which co-founded, seeded, and incubated the company, along with Lilly Ventures and Amgen Ventures.